Mineralys Therapeutics, Inc. (MLYS) vs Palvella Therapeutics, Inc. (PVLA)

A side-by-side comparison of Mineralys Therapeutics, Inc. and Palvella Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Mineralys Therapeutics, Inc. logo
MLYS
Mineralys Therapeutics, Inc.
$1.94B
$21.95HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Palvella Therapeutics, Inc. logo
PVLA
Palvella Therapeutics, Inc.
$1.84B
$128.00HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — MLYS vs PVLA

growth of $100 · dividends reinvested · last 2y
MLYS +77.3% (+33.2%/yr)PVLA +677.4% (+178.8%/yr)PVLA compounded faster over this window
0200400600800Start $10020252026$177$777
MLYS PVLA

MLYS vs PVLA: by the numbers

  • •MLYS is the larger company ($1.94B vs $1.84B market cap).

Metrics side by side

Valuation

MetricMLYSPVLA
P/B ratio3.518.47

Profitability

MetricMLYSPVLA
Gross margin0.00%0.00%
Operating margin0.00%0.00%
Net margin0.00%0.00%
ROE-63.45%-28.45%
ROIC-57.17%-23.90%

Go deeper

Full MLYS analysisFull PVLA analysisInteractive comparison tool

Dig into the metrics

Mineralys Therapeutics ROEPalvella Therapeutics ROEMineralys Therapeutics operating marginPalvella Therapeutics operating marginMineralys Therapeutics revenue growthPalvella Therapeutics revenue growthMineralys Therapeutics free cash flowPalvella Therapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.